About Cardium: Business Strategy

Building upon our core products and product candidates, our strategic goal is to develop a portfolio of medical products at advanced stages of development and secure additional financial resources to commercialize these products in a timely and effective manner. The key elements of our strategy are to:

• Advance the AWARE Phase 3 clinical study for Generx in women with recurrent angina to treat myocardial ischemia;
• Advance the MATRIX Phase 2b clinical study of Excellarate, a topical collagen-based gel for patients with chronic diabetic wounds and seek partnering opportunities;
• Accelerate commercialization of InnerCool’s endovascular and surface temperature modulation systems with an expanded sales force and increased manufacturing capacity;
• Advance the pre-clinical development of Corgentin and potentially seek partnering opportunities for the Corgentin and Genvascor product candidates;
• Maintain small corporate infrastructure through the use of contract service providers; and
• Continue to utilize Cardium as a platform to acquire other companies, secure additional capital and product opportunities to diversify risk and accelerate growth to enhance shareholder value.